Updates on Recent Advancements in Hepatitis D Virus Treatment

Area of Science:

• Hepatology
• Virology
• Infectious Diseases

Background:

• Hepatitis D virus (HDV) infection significantly worsens liver disease in hepatitis B virus (HBV) patients, accelerating cirrhosis and hepatocellular carcinoma.
• Current first-line therapy, pegylated interferon-alfa, has limited efficacy, poor response durability, and significant side effects for HDV.
• The lack of effective treatments highlights the urgent need for novel therapeutic strategies.

Purpose of the Study:

• To provide an overview of recent advancements in the treatment of chronic Hepatitis D virus infection.
• To discuss emerging novel therapies and their potential impact on managing HDV.
• To highlight the evolving landscape of HDV treatment options.

Main Methods:

• This review synthesizes current literature on Hepatitis D virus (HDV) treatment.
• It focuses on approved therapies and those in clinical investigation.
• Key advancements and challenges in HDV therapy are discussed.

Main Results:

• Pegylated interferon-alfa is the current standard but has limitations.
• Bulevirtide, an entry inhibitor, is the first approved agent for chronic HDV by the EMA.
• Several other promising therapies are under investigation.

Conclusions:

• The treatment landscape for Hepatitis D virus infection is evolving with new therapeutic options.
• Bulevirtide represents a significant advancement, with further novel agents in development.
• Improved treatment strategies are crucial for better outcomes in patients with chronic HDV infection.